Area of research
Hematology · Cancer Research
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Ovarian cancer diagnosis and treatment.
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial
IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease
The Space Omics and Medical Atlas (SOMA) and international astronaut biobank
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
Genome and clonal hematopoiesis stability contrasts with immune, cfDNA, mitochondrial, and telomere length changes during short duration spaceflight
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation
Clonal hematopoiesis in survivors of childhood cancer
The age-related deceleration of clonal haematopoiesis in 420,000 healthy adults
Genome and Clonal Hematopoiesis Stability Contrasts with Immune, cfDNA, mitochondrial, and telomere length changes to Short Duration Spaceflight
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Clonal Hematopoiesis and Risk of Incident Lung Cancer
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Single-cell mutation analysis of clonal evolution in myeloid malignancies
Clonal Hematopoiesis Before, During, and After Human Spaceflight
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays
Managing Clonal Hematopoiesis in Patients With Solid Tumors